151 related articles for article (PubMed ID: 17428104)
21. Results of a phase II open-label, nonrandomized trial of oral satraplatin in patients with metastatic breast cancer.
Smith JW; McIntyre KJ; Acevedo PV; Encarnacion CA; Tedesco KL; Wang Y; Asmar L; O'Shaughnessy JA
Breast Cancer Res Treat; 2009 Nov; 118(2):361-7. PubMed ID: 19459042
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of satraplatin in dogs with spontaneously occurring malignant tumors.
Selting KA; Wang X; Gustafson DL; Henry CJ; Villamil JA; McCaw DL; Tate D; Beittenmiller M; Garnett C; Robertson JD
J Vet Intern Med; 2011; 25(4):909-15. PubMed ID: 21564292
[TBL] [Abstract][Full Text] [Related]
23. [Ototoxicity of cis-diammine glycolato platinum, 254-S].
Horiuchi M; Miyake H; Ota K
Gan To Kagaku Ryoho; 1992 Aug; 19(9):1327-32. PubMed ID: 1503488
[TBL] [Abstract][Full Text] [Related]
24. Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies.
Culy CR; Clemett D; Wiseman LR
Drugs; 2000 Oct; 60(4):895-924. PubMed ID: 11085200
[TBL] [Abstract][Full Text] [Related]
25. Future directions in the treatment of androgen-independent prostate cancer.
Petrylak DP
Urology; 2005 Jun; 65(6 Suppl):8-12. PubMed ID: 15939077
[TBL] [Abstract][Full Text] [Related]
26. Current and future potential roles of the platinum drugs in the treatment of ovarian cancer.
Piccart MJ; Lamb H; Vermorken JB
Ann Oncol; 2001 Sep; 12(9):1195-203. PubMed ID: 11697824
[TBL] [Abstract][Full Text] [Related]
27. Clinical and pharmacokinetic evaluation of satraplatin.
Doshi G; Sonpavde G; Sternberg CN
Expert Opin Drug Metab Toxicol; 2012 Jan; 8(1):103-11. PubMed ID: 22098065
[TBL] [Abstract][Full Text] [Related]
28. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
[TBL] [Abstract][Full Text] [Related]
29. The plasma and cerebrospinal fluid pharmacokinetics of the platinum analog satraplatin after intravenous administration in non-human primates.
Marcus L; Murphy R; Fox E; McCully C; Cruz R; Warren KE; Meyer T; McNiff E; Balis FM; Widemann BC
Cancer Chemother Pharmacol; 2012 Jan; 69(1):247-52. PubMed ID: 21706317
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics of satraplatin (JM216), an oral platinum (IV) complex under daily oral administration for 5 or 14 days.
Vouillamoz-Lorenz S; Buclin T; Lejeune F; Bauer J; Leyvraz S; Decosterd LA
Anticancer Res; 2003; 23(3C):2757-65. PubMed ID: 12926110
[TBL] [Abstract][Full Text] [Related]
31. Satraplatin in the treatment of hormone-refractory prostate cancer.
Sternberg CN
BJU Int; 2005 Nov; 96(7):990-4. PubMed ID: 16225514
[No Abstract] [Full Text] [Related]
32. [Development of carboplatin].
Tsukagoshi S
Gan To Kagaku Ryoho; 1990 Sep; 17(9):1949-58. PubMed ID: 2203318
[TBL] [Abstract][Full Text] [Related]
33. Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin.
Samimi G; Kishimoto S; Manorek G; Breaux JK; Howell SB
Cancer Chemother Pharmacol; 2007 Feb; 59(3):301-12. PubMed ID: 16770583
[TBL] [Abstract][Full Text] [Related]
34. Satraplatin in the treatment of hormone-refractory metastatic prostate cancer.
Armstrong AJ; George DJ
Ther Clin Risk Manag; 2007 Oct; 3(5):877-83. PubMed ID: 18473011
[TBL] [Abstract][Full Text] [Related]
35. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
[TBL] [Abstract][Full Text] [Related]
36. Platinum compounds in the treatment of advanced breast cancer.
Martín M
Clin Breast Cancer; 2001 Oct; 2(3):190-208; discussion 209. PubMed ID: 11899413
[TBL] [Abstract][Full Text] [Related]
37. Modulation of the cellular pharmacology of JM118, the major metabolite of satraplatin, by copper influx and efflux transporters.
Samimi G; Howell SB
Cancer Chemother Pharmacol; 2006 Jun; 57(6):781-8. PubMed ID: 16170571
[TBL] [Abstract][Full Text] [Related]
38. A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel.
Ross RW; Beer TM; Jacobus S; Bubley GJ; Taplin ME; Ryan CW; Huang J; Oh WK;
Cancer; 2008 Feb; 112(3):521-6. PubMed ID: 18085595
[TBL] [Abstract][Full Text] [Related]
39. Combination of nedaplatin and vindesine for treatment of relapsed or refractory non-small-cell lung cancer.
Takigawa N; Segawa Y; Ueoka H; Kiura K; Tabata M; Shibayama T; Takata I; Miyamoto H; Eguchi K; Harada M
Cancer Chemother Pharmacol; 2000; 46(4):272-8. PubMed ID: 11052624
[TBL] [Abstract][Full Text] [Related]
40. Oxaliplatin in first-line therapy for advanced non-small-cell lung cancer.
Raez LE; Kobina S; Santos ES
Clin Lung Cancer; 2010 Jan; 11(1):18-24. PubMed ID: 20085863
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
